Evaluation of vascular endothelial growth factor and tumor microvessel density in prognoses of patients with breast cancer: A follow-up of 1-10 years
Hongjiang Li,Jing Jing,Lin Chen,Qing Lü,Jing Wang,Yangbing Zhao
2004-01-01
Abstract:Aim: To observe the expression of vascular endothelial growth factor(VEGF) and the distribution of microvessel density(MVD) in breast carcinoma and benign breast disease, discuss the relationship of MVD and VEGF with the tumor size(T), histological grade, the level of estrogen receptor and axillary lymphatic metastasis, and relapse and metastasis, and evaluate the prognostic value of MVD and VEGF. Methods: The pathological sections were stained by immunohistochemical staining using antibody of vascular endothelium for factor VIII antigen and multiclone antibody of anti-VEGF respectively. Under the microscope, the stained degree of VEGF were observed, and the contribution of microvessel counting was calculated. The prognoses of patients were followed up. Results: In the breast cancer and benign breast disease, the positive rates of VEGF expression were 51.35% and 16.13% respectively(χ 2=11.21, P <0.005), and the mean levels of MVD were (30.8±19.4) and (16.09±7.9) every 200 times sight respectively(t=4.47, P <0.01). MVD was associated with tumor size(t=2.0, P <0.05), histological grade (F = 3.48, P <0.05), axillary lymphatic metastasis(χ2=4.24, P < 0.05), and relapse and metastasis(t=2.84, P <0.05), and VEGF was related to axillary lymphatic metastasis(χ2=5.62, P <0.05) and relapse and metastasis(χ2=5.13, P <0.05). The relapse-free survival rate was significantly associated with VEGF(χ 2=5.12, P <0.05) and MVD (χ2= 8.752, P <0.05). Moreover, there was no obvious correlation between MVD and VEGF. Conclusion: The distribution of MVD and the postive rate of VEGF expression in breast carcinoma were significantly higher than those of benign breast disease. VEGF and MVD of breast carcinoma, related to the prognoses of patients, can be regarded as a prognostic indicator for the patients with breast cancer. VEGF is not the only factor influencing tumor angiogenesis.